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Purpose:  2 
The main purpose of this study was to test the hypothesis that incidental cardiac irradiation is associated with 3 
changes in cardiac function in breast cancer (BC) survivors treated with radiotherapy (RT). 4 
 5 
Methods and Materials:  6 
We conducted a cross-sectional study consisting of 109 BC survivors treated with RT between 2005 and 2011. 7 
The endpoint was cardiac function, assessed by echocardi graphy. Systolic function was assessed with the left 8 
ventricle ejection fraction (LVEF) (n=107) and the global longitudinal strain (GLS) of the left ventricle (LV) 9 
(n=52). LV diastolic dysfunction (n=109) was defined by e’ at the lateral and septal region, which represents the 10 
relaxation velocity of the myocardium. The individual calculated RT dose parameters of the LV and coronary 11 
arteries were collected from three-dimensional CT-based planning data. Univariable and multivariable analysis 12 
using forward selection was performed to identify the best predictors of cardiac function. Robustness of election 13 
was assessed using bootstrapping. The resulting multivariable linear regression model was presented for the 14 
endpoints systolic and diastolic function. 15 
 16 
Results: 17 
The median time between BC diagnosis and echocardiography was 7 years. No relation between RT dose 18 
parameters and LVEF was found. In the multivariable analysis for the endpoint GLS of the LV, the maximum 19 
dose to the left main coronary artery was most often s lected across bootstrap samples. For decreased diastolic 20 
function the most often selected model across bootstrap samples included age at time of BC diagnosis and 21 
hypertension at baseline. Cardiac dose-volume histogram (DVH) parameters were less frequently selected for 22 
this endpoint. 23 
 24 
Conclusions: 25 
This study shows an association between individual cardiac dose distributions and GLS of the LV after RT for 26 
BC. No relation between RT dose parameters and LVEF was found. Diastolic function was most associated with27 
















Adjuvant radiotherapy (RT) for breast cancer (BC) has been associated with a wide variety of cardiac diseases1. 2 
In relation to BC radiation, risk of ischemic heart disease has been well-established2,3,4. Recent studies have 3 
shown significant relationships between RT to the whole heart (WH) and left ventricle (LV), and acute coronary 4 
events in BC populations5,6. However, the relationship between thoracic RT and car iac dysfunction is less clear.  5 
The left ventricular ejection fraction (LVEF) by echocardiography is the cornerstone of LV systolic function 6 
assessment in clinical practice. However, LVEF can underestimate actual cardiac damage because of the 7 
compensatory reserve of the myocardium that enables ad quate ventricular outcome even in the presence of 8 
dysfunctional myocytes7. Global longitudinal systolic strain (GLS) is an echocardiographic technique that 9 
detects and quantifies subclinical and subtle disturbances in LV systolic function and can thus be considered as 10 
early marker for radiation-induced cardiac damage8. This is particularly relevant, as the latency time for 11 
symptomatic radiation-induced cardiovascular diseases i  relatively long. These early markers may be helpful to 12 
identify patients at risk for major cardiac events that may benefit from preventive strategies.  13 
The aim of this study was to assess the relationship between radiation dose to the LV and radiation dose t  the 14 
coronary arteries and LV systolic and diastolic function in BC survivors treated with RT based on individual 15 
planned 3D dose distributions and computed tomography (CT) information. 16 
 17 
METHODS AND MATERIALS 18 
Study Population 19 
The Department of General Practice of XXXX performed a cross-sectional population-based study to assess th  20 
frequency of cardiac dysfunction in female BC survivors in a primary care setting9. Patients were included if 21 
they were diagnosed with BC stage I–III and had no disease activity for at least 5 years after treatmen . 22 
Information could be extracted from electronic patien  records of one of 80 participating primary care physicians 23 
(PCPs) in the northern Netherlands region. Patients were excluded if they had metastatic disease at the ime of 24 
BC diagnosis, had a history of other malignancies and/or received prior chemotherapy or RT treatment for other 25 
malignancies. The main study included 350 BC survivors treated from 1988 to 2011. All 350 patients underwent 26 
an echocardiography. Due to the inclusion criteria of the main study with the date of treatment mostly in the pre-27 
CT era, patients were only selected when CT-based RT treatment planning data was available. Therefore, ur 28 
total study population was composed of 109 BC survivo s treated with RT from 2005 to 2011.  29 
All patients were treated with breast conserving surgery followed by adjuvant RT. Patients with node positive 30 
disease and high risk node negative patients were tr ated with adjuvant systemic treatment including edocrine 31 
therapy, according to the national guidelines. 32 
 33 
Data Collection 34 
Citizens of the Netherlands are registered in an electronic record of a primary care physician (PCP). The PCP 35 
captures all information according to the International Classification of Primary Care (ICPC)10. Relevant data 36 
was collected using the ICPC codes for cardiovasculr risk factors (dyslipidemia, hypertension, and diabetes 37 
mellitus) and cardiovascular disease (heart failure, ischemic heart disease, acute myocardial infarction, coronary 38 















Detailed information about patient characteristics, tumor characteristics, systemic BC therapy (including 1 
chemotherapy and/or endocrine therapy and/or Trastuzumab), and follow-up data were retrieved from hospital 2 
charts. The baseline date was defined as the date of BC diagnosis. The censoring date was defined as the date of 3 
the echocardiographic assessment. The medical ethics committee of XXXX approved the study which was 4 
registered at clinicaltrials.gov [ID:XXXX]9. 5 
 6 
Radiation Dosimetry 7 
All 109 patients were treated with 3D conformal RT using CT-based treatment planning11. At the time of 8 
inclusion, cardiac sparing using e.g. breath holding techniques was not yet implemented. Therefore, none of the 9 
patients were treated with a breath-hold technique. The reported doses are therefore higher than the typical 10 
cardiac exposure with modern planning and cardioprotective techniques12. The prescribed dose was 50.4 Gy 11 
delivered in 28 fractions to the whole breast with a simultaneous integrated boost of 14.0 or 16.8 Gy to a boost 12 
volume in the same 28 fractions, depending on pathological risk factors.  13 
To analyze the relationship between cardiac functio of the LV and incidental cardiac irradiation, contouring 14 
was performed of the LV and coronary arteries, respon ible for the oxygenation of the LV. The LV was 15 
contoured using a multi-atlas automatic segmentation to l based on the delineations by Feng t al. (Mirada RTx 16 
[version 1.6]; Mirada Medical, Oxford, United Kingdom)13. The contouring of the coronary arteries, including 17 
the left main coronary artery (LMCA), left anterior descending coronary artery (LAD) and circumflex coronary 18 
artery (CX) and right coronary artery (RCA) was based on a recently published cardiac contouring guideline by 19 
Duane et al.14 and was done manually by one observer (example of a 3D reconstruction is shown in figure 1). 20 
Following cardiac substructure delineation, the individual radiation dose to these substructures was re-calculated 21 
using the original treatment plan. As a final step for this study, dose-volume histogram (DVH) parameters of the 22 
cardiac substructures were extracted from the treatm nt planning system (Pinnacle [version 9.1]; Philips 23 
Radiation Oncology, Fitsburg, WI). 24 
  25 
Echocardiography Parameters 26 
As described previously, cardiac (dys)function was evaluated using echocardiography9. In short, all image 27 
acquisition and analysis was performed by a central reading lab (XXXX Imaging Core Laboratory) with VIID 28 
E9 ultrasound equipment (GE, Horton, Norway), based on a predefined imaging and measurement protocol. All 29 
measurements were performed in accordance with the guidelines of the European Association for Cardio 30 
Vascular Imaging/American Society of Echocardiography (EACVI/ASE)15.  31 
Systolic function was evaluated in two ways. First by the left ventricular ejection fraction (LVEF) whic  was 32 
measured by the biplane method of disks summation (modified Simpson’s rule). In cases where the image 33 
quality was too low to reliably determine the endocardial border, an estimation of LVEF was given by an 34 
experienced ultrasound technician. The LVEF was analyzed for 107 patients. Abnormal LVEF was defined as an 35 
LVEF <54%, according to the EACVI/ASE guidelines15. Additionally, global longitudinal systolic strain (GLS) 36 
was determined as another measure of systolic function. For this reason, the echocardiograms were 37 
retrospectively analyzed for the GLS of the LV, using automated 2D-speckle-tracking with TomTec Imaging 38 
Systems GmbH Arena 2 (Munich, Germany). For this analysis, we excluded all echocardiographies that were 39 















The remaining 71 echocardiographies were measured using Simpson’s biplane method. Of those, 19 were 1 
excluded due to persistent inadequate tracking of GLS segments, or due to incorrect tracing of the apex. 2 
Furthermore, the echocardiographies were checked for reproducibility of GLS by analyzing inter- and intra-3 
observer variability. The interclass correlation coefficient (ICC) was determined and accepted if ICC was greater 4 
than 0.616,17. As a result, the GLS of the LV was retrospectively analyzed for 52 patients (flow-chart figure 1 in 5 
the supplemental material). 6 
LV diastolic dysfunction was analyzed for 109 patients and defined by e’ at the lateral and septal region, where 7 
e’ represents the relaxation velocity of the myocardium in early diastole. Diastolic dysfunction was defined as e’ 8 
lateral or e’ septal at 2.5% below the normal range for each age group, according to the European Associati n of 9 
Echocardiography/American Society of Echocardiography (EAE/ASE)18. By calculating the average of e’ septal 10 
and e’ lateral together, a continuous variable was created19.  11 
 12 
Statistical Analysis 13 
Patient characteristics (including cardiovascular risk factors (diabetes mellitus, hypertension, dyslipidemia, 14 
smoking, and body mass index (BMI)), cardiac diseases (heart failure, arrhythmias, non-rheumatic valve 15 
disorder, and ischemic heart disease)), tumor charateristics and information about BC systemic treatment 16 
(chemotherapy, endocrine therapy and/or Trastuzumab) and RT were described at the time of diagnosis and if 17 
applicable at the time of echocardiography using descriptive statistics. Clinical factors at time of diagnosis were 18 
included in the analysis, as pre-existing cardiac conditions in combination with RT were found to increase the 19 
risk of subsequent cardiac events5,6. Arrhythmias included supraventricular tachycardia, ventricular paroxysmal 20 
tachycardia and/or atrial fibrillation. Non-rheumatic valve disorder included aortic stenosis and/or mit al valve 21 
insufficiency. Ischemic heart diseases included corona y atherosclerosis, myocardial infarction and/or angina 22 
pectoris. Using DVH data from each patient’s RT plan, we first calculated the mean dose, maximum dose and 23 
mean V(x) in bins of 5 Gy, where V(x) refers to therelative volume (in percentage) of the cardiac substr ctures 24 
that received a dose of x Gy. Both systolic and diastolic function was defined as binary variables and s 25 
continuous variables, whenever appropriate. 26 
The first step in identifying associations between patient characteristics, risk factors and treatment characteristics 27 
and the endpoints systolic and diastolic function, was a pre-selection based on intervariable correlation to reduce 28 
the number of variables. If the Pearson correlation of two variables was larger than 0.80, the variable with the 29 
strongest univariable association with the endpoint was selected20. Secondly, univariable and multivariable 30 
stepwise forward selection was used to select the most important risk factors. The entire variable selection 31 
procedure (pre-selection and forward selection) was repeated on 1000 bootstrapped samples of equal size a  the 32 
original study population and that were drawn with replacement. The resulting, most frequently selected, 33 
multivariable linear regression model was presented. This analysis was done for the endpoints LVEF, GLS of the 34 
LV and diastolic function, respectively. Data was analyzed using Matlab (version R2017a) and SPSS (IBM 35 
SPSS Statistics, Version 22, IBM Corp). 36 
 37 
RESULTS 38 















The characteristics of the patients at baseline and at the time of echocardiography are summarized in table 1. 1 
Tumor- and treatment characteristics are summarized in table 2. The median age at diagnosis was 55 years 2 
(interquartile range (IQR)=49–60), and the median age t time of echocardiography was 62 years (IQR=56–67). 3 
The median follow-up time was 7 years (IQR=5–8). 4 
 5 
Results Echocardiography 6 
Systolic function 7 
The results of echocardiography are summarized in table 3. Using LVEF <54% as a cut-off value, 15 out f 107 8 
(14%) BC survivors had an abnormal LVEF at the time of chocardiography.  9 
We further analyzed the data by investigating a possible relationship between radiation dose and post-treatment 10 
LVEF. Clinical factors (age, diabetes mellitus, hypertension, dyslipidemia, smoking, and number of pack years), 11 
systemic therapy (chemotherapy, endocrine therapy, nd Trastuzumab) and DVH parameters (mean dose, 12 
maximum dose, and mean V(x) in bins of 5 Gy) of theLV and coronary arteries were entered in the 13 
multivariable analysis before application of forward selection. Results of the variable selection in the 1000 14 
bootstrap samples are shown in supplementary material figures 2 and 3. No relationships with RT dose 15 
parameters or use of systemic therapy were found. In the final model, LVEF was associated with smoking at 16 
time of diagnosis (supplementary material table 1). 17 
As a decreased LVEF indicates relatively late and severe cardiac damage, we performed an additional analysis 18 
using the subclinical parameter GLS of the LV as an endpoint. Based on 52 echocardiographies, the mean GLS 19 
of the LV was -16.95% (range=-23.26%– -9.44%). Based on the multivariable analysis, that included the 20 
following risk factors before variable selection: clinical factors (age, diabetes mellitus, hypertensio , 21 
dyslipidemia, smoking, and number of pack years), systemic therapy variables (chemotherapy, endocrine 22 
therapy, and Trastuzumab) and DVH parameters (mean dose, maximum dose, and mean V(x) in bins of 5 Gy) of 23 
the LV and coronary arteries, we found that the maxi um dose to the LMCA was selected most across bootstrap 24 
samples (supplementary material figure 4). All DVH parameters that were selected related to dose to the 25 
coronary arteries, not to the LV. The frequency plot of the selected models is shown in figure 5 in the26 
supplementary material. Model characteristics of the final model for the endpoint GLS of the LV, consisting of 27 
the maximum dose to the LMCA, are shown in Table 4. 28 
 29 
Diastolic function 30 
Using e’ lateral or e’ septal at 2.5% below the normal range for each age group as a cut-off value, 43 out of 109 31 
(39%) BC survivors had a diastolic dysfunction (table 2). 32 
Based on the multivariable analysis, that included the same risk factors before variable selection: cli ical factors 33 
(age, diabetes mellitus, hypertension, dyslipidemia, smoking, and number of pack years), systemic therapy 34 
variables (chemotherapy, endocrine therapy, and Trastuzumab) and DVH parameters (mean dose, maximum 35 
dose, and mean V(x) in bins of 5 Gy) of the LV and coronary arteries, we found that clinical variables were 36 
selected most across bootstrap samples (supplementary material figure 6). The variable age at baseline was 37 
selected 1000 times out of 1000 bootstrap samples and hypertension at baseline was selected 629 times. DVH 38 















figure 7 in the supplementary material. Details of the final model for the endpoint diastolic function, consisting 1 
of age at baseline and hypertension, are shown in Table 5. 2 
 3 
DISCUSSION 4 
This study shows an association between individual cardiac dose distributions and subclinical systolic 5 
dysfunction of the LV after RT for BC. The subclinical marker, GLS of the LV, was most associated with the 6 
maximum dose to the LMCA. Notable, all DVH parameters that were selected for this endpoint were based on 7 
dose to the coronary arteries. The final model for diastolic function included age and hypertension at baseline. 8 
DVH parameters were less frequently selected for this endpoint. 9 
Previous studies have shown similar results with rega d to systolic function using LVEF as a primary 10 
endpoint21,22,23. In these studies, with a median follow-up time of 6 to 13 years, no significant decrease in LVEF 11 
after RT treatment for BC has been observed21,22,23. Additionally, in a recently published meta-analysis, RT was 12 
found to be associated with an increased risk of coronary heart disease, but not with a significant declin  in 13 
LVEF4. In the current study based on 3D cardiac dose distributions, no relation between RT dose and decline in 14 
LVEF was found either. It should be noted that changes in LVEF reflect severe damage that may manifest itself 15 
relatively late, due to compensation mechanisms24. Given the median follow-up time in the current study of 7 16 
years, the interval may be too short for the development of a decreased LVEF of <54%. Because of the 17 
limitations in sensitivity and reproducibility of the LVEF, we decided to also use the GLS of the LV which is a 18 
more sensitive method to detect subclinical systolic dysfunction of the LV25.  19 
Two studies looked at both LVEF and GLS in BC survivors26,27. They found no significant decrease in LVEF 20 
after RT in patients with either left- or right-side  BC between two and 14 months of follow-up. However, a 21 
significant decrease in longitudinal strain immediately after RT and at 8 and 14 months after RT was found for 22 
left-sided BC survivors, but not for right-sided BC survivors suggesting a dose effect relationship. Another study 23 
found that patients with left-sided BC experienced a ecline in apical and global strain values, whereas patients 24 
with right-sided BC showed a decline in the basal anterior segment of the LV. Furthermore, RT caused no 25 
changes in conventional LV systolic measurements28. However, the researchers did not examine any associations 26 
between cardiac dose parameters and GLS of the LV. In line with the current study, these results indicate that 27 
GLS is a more sensitive measure for cardiac changes aft r BC RT and that these changes are already present 28 
relatively early after completion of RT treatment.  29 
Several studies suggest that GLS provides independent prognostic information regarding cardiovascular 30 
morbidity and mortality in the general population29,30,31. Presence of worse LV strain at baseline, was associated 31 
with higher risk for incident heart failure and all-cause mortality over the follow‐up period31. This is particularly 32 
important in BC populations, as it may take years fo  clinically overt cardiac damage to develop. The detection 33 
of early changes could be predictive for late RT-induced cardiac morbidity26. 34 
Knowledge on the exact underlying mechanism behind ra iation-induced cardiac toxicity is lacking. In 35 
particular, it is not clear whether coronary artery damage or myocardial damage, or both, are responsible for 36 
radiation-induced heart disease32. Our results suggest that RT to the coronary arteries is associated with 37 
subclinical systolic dysfunction. As shown in table 4, the most selected risk factor of post-treatment GLS is the 38 
maximum dose to the LMCA. This was also supported by the frequency tables in the supplemental material, 39 















myocardium. Previous research has shown a direct link between radiation dose and the location of coronary 1 
stenosis, mostly in the LAD33,34. These studies support the importance of the coronary arteries in the 2 
pathogenesis of radiation-induced cardiac toxicity. 3 
It could be hypothesized that radiation of coronary teries may initiate inflammation, coronary spasms, or 4 
rupture of an existing atherosclerotic plaque, resulting in insufficient supply of oxygenated blood tohe 5 
myocardium. This can eventually lead to secondary dmage to the myocardium, in addition to direct radiation-6 
induced local damage to the microvascular endothelial cells leading to microvascular rarefaction and myocardial 7 
inflammation, oxidative stress and fibrosis35,36. However, the exact mechanisms of radiation-associated cardiac 8 
damage still remain to be determined.  9 
We found an association between clinical variables and diastolic function. Our results showed that agend 10 
hypertension at time of BC diagnosis were selected most for the endpoint diastolic function in the 1000 bootstrap 11 
samples. This is consistent with previous studies that have also shown no significant increased risk of LV 12 
diastolic dysfunction after BC treatment9,23,37.  13 
A limitation of our study is its cross-sectional design. We did not have echocardiography data prior to RT and 14 
therefore we are not able to report on possible changes after RT. However, the relationship found for systolic 15 
(GLS) function suggests that RT might play a role in the etiology of these effects. The decline in cardiac 16 
function in relation to the dose of radiation is subtle. This subtlety makes it difficult to identify differences 17 
between patient groups and control groups. By using dose effect relationships we are able to identify small 18 
changes that cannot be found just by comparing irradiated and non-irradiated populations.  19 
It was also possible to take into account patient age nd follow-up time; although in our analysis age was not 20 
associated with the decline in systolic cardiac function, but it was associated with a decline in diastolic function. 21 
Follow-up time was not associated with systolic or diastolic function. Moreover, it is important to note that we 22 
performed explorative analysis in this study. Therefore prospective data still needs to be collected within studies 23 
such as the BACCARAT prospective cohort study or the MEDIRAD EARLY HEART study8,38. The results of 24 
the current study should therefore be considered as hypothesis generating, and not for making definitive 25 
conclusions. Further research and validation in other and larger cohorts is needed to confirm our results. 26 
Another limitation is that it remains to be determined if, in this specific group of patients, subclini al effects will 27 
eventually translate into major cardiac events. However, as shown in the general population, GLS provides 28 
independent and additional prognostic information regarding long-term risk of cardiovascular morbidity and 29 
mortality29. 30 
In conclusion, this study shows an association betwe n individual RT dose for BC and GLS of the LV. Our 31 
results suggest that these adverse effects are associ ted with radiation dose to the coronary arteries. Diastolic 32 
function was associated with age and hypertension at time of BC diagnosis, DVH parameters were less 33 
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Figure legend 1: Example of the contouring of the coronary arteries 1 
The left ventricle (LV) was contoured using a multi-atlas automatic segmentation tool based on the delineations 2 
by Feng et al.. The contouring of the coronary arteries, including the left main coronary artery (purple), left 3 
anterior descending coronary artery (orange) and circumflex coronary artery (green) and right coronary tery 4 













Table 1: Patient characteristics at the time of breast cancer diagnosis and at the time of 
echocardiography for all 109 breast cancer survivors 
BC population (N = 109) 
Variable At baseline At time of echocardiography 
Age at BC diagnosis, years 
Median 
IQR 














Cardiovascular risk factors 















































Cardiac diseases*  






Non-rheumatic valve disorder (%)‡ 
Yes 
No 










































*: as reported by their primary care physician or stated in their hospital medical charts. 
†: arrhythmias included supraventricular paroxysmal tachycardia, ventricular paroxysmal tachycardia and/or 
atrial fibrillation. 
‡: non-rheumatic valve disorder included aortic stenosis and/or mitral valve insufficiency. 




































Table 2: Tumor and treatment characteristics at the time of breast cancer diagnosis for all 109 breast 
cancer survivors 
Tumor characteristics (%) 
Laterality BC 
Left (-sided BC) 





























Radiotherapy, median (range) (Gy) 

































































Endocrine therapy only 
Yes 
No 



















Abbreviations: BC, breast cancer; T, tumor; N, nodes; Gy, gray; LV, left ventricle; LMCA, left main cor nary 




























Table 3: Results of echocardiography after a median follow-up time of 7 years 
Variable  % 
























Left ventricle global longitudinal strain (%) based on 52 BC patients‡ 
Mean 
Range 













Abnormal left ventricle diastolic function|| 
Yes 
No 

















Abbreviations: BC, breast cancer 
*: measured left ventricle ejection fraction (LVEF) with biplane method of disks summation (modified 
Simpson’s rule), if not available with eyeballing. 
†: defined as a LVEF <54% according to the European Association for Cardio Vascular Imaging/American 
Society of Echocardiography. 
‡: measured using automated two-dimensional-speckle-tracking. 
§: average of the mean e’ septal and e’ lateral. 
||: defined as e’ lateral or e’ septal 2.5% below the normal range for each age group, according to the European 
Association of Echocardiography/American Society of Echocardiography. In this cohort the mean e’ septal was 


















Table 4: Model characteristics of the final model for the endpoint global longitudinal systolic strain of the 
left ventricle in breast cancer survivors within first 10 years after RT. Results are based on 52 breast 
cancer survivors. 
Variable B SE 95% CI for B P-value*  
Dmax LMCA 0.883 0.342 0.195–1.570 0.013 
Abbreviations: RT, radiotherapy; B, regression coeffici nt; SE, standard error; CI, confidence interval; D, dose; 
LMCA, left main coronary artery 

































Table 5: Model characteristics of the final model for the endpoint diastolic function of the left ventricle in 
breast cancer survivors within first 10 years after RT. Results are based on 109 breast cancer survivors. 
Variable B SE 95% CI for B P-value*  
Age at BC diagnosis -0.155 0.021 -0.197–-0.133 0.000 
Hypertension -1.309 0.536 -2.372–-0.246 0.016 
Abbreviations: RT, radiotherapy; B, regression coeffici nt; SE, standard error; CI, confidence interval 































The relationship between individual cardiac dose distributions and systolic and diastolic dysfunction is unclear. 2 
We conducted a cross-sectional study consisting of 109 breast cancer survivors treated with post-operative 3 
radiotherapy (RT). The endpoint was systolic and diastolic cardiac function, assessed by echocardiography. 4 
Although no relation between RT dose parameters and left ventricle ejection fraction was found, an association 5 
between individual RT dose and global longitudinal systolic strain of the left ventricle was determined. 6 
